CSL (OTCMKTS:CSLLY) Downgraded by Royal Bank Of Canada to “Hold”

Royal Bank Of Canada downgraded shares of CSL (OTCMKTS:CSLLY) from a moderate buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

A number of other equities research analysts have also commented on CSLLY. Canaccord Genuity Group raised shares of CSL from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

CSL Trading Down 3.7%

CSL stock opened at $56.82 on Wednesday. CSL has a 52 week low of $54.10 and a 52 week high of $89.71. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The business’s fifty day moving average is $59.98 and its two-hundred day moving average is $65.73.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.